| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | IMPD; RP10; IMPD1; LCA11; sWSS2608 |
| WB Predicted band size | 55 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human IMPDH1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下为3篇关于IMPDH1抗体的示例文献(注：文献信息为示例性概括，实际文献需通过学术数据库验证)：
1. **文献名称**: "IMPDH1 as a prognostic biomarker in acute myeloid leukemia"
**作者**: Smith J, et al.
**摘要**: 研究通过IMPDH1抗体检测发现，IMPDH1在AML患者骨髓细胞中高表达，其表达水平与化疗耐药性相关，提示其可作为潜在治疗靶点。
2. **文献名称**: "Structural analysis of IMPDH1 isoforms using monoclonal antibodies"
**作者**: Chen L, et al.
**摘要**: 开发了特异性识别IMPDH1的单克隆抗体，通过免疫印迹和免疫荧光证实IMPDH1在不同细胞系中的亚细胞定位差异，为酶活性调控机制提供依据。
3. **文献名称**: "IMPDH1 inhibition modulates T-cell responses in autoimmune disorders"
**作者**: Gupta R, et al.
**摘要**: 利用IMPDH1抗体研究其在T细胞活化中的功能，发现抑制IMPDH1可降低炎症因子分泌，为治疗类风湿性关节炎等疾病提供新思路。
**提示**：实际文献建议通过PubMed/Google Scholar以关键词"IMPDH1 antibody" + 研究领域(如癌症、免疫调控)检索，并筛选近5年高被引论文。部分研究可能侧重抗体应用(WB/IHC)或疾病机制探索。
IMPDH1 (Inosine-5'-monophosphate dehydrogenase type 1) is a critical enzyme in the de novo biosynthesis of guanine nucleotides, catalyzing the oxidation of IMP to XMP—a rate-limiting step in purine metabolism. It exists as two isoforms (IMPDH1 and IMPDH2) with distinct tissue expression patterns. IMPDH1 is constitutively expressed in most tissues, while IMPDH2 is induced during cell proliferation. Antibodies targeting IMPDH1 are widely used to study its expression, localization, and regulatory roles in cellular processes like proliferation, differentiation, and apoptosis.
IMPDH1 antibodies (monoclonal or polyclonal) are essential tools for detecting the protein via techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Researchers often validate antibody specificity using IMPDH1-knockout cell lines or siRNA-mediated knockdown. These antibodies help investigate IMPDH1 dysregulation in diseases, including cancer (e.g., leukemia, colorectal cancer), where its overexpression correlates with aggressive phenotypes, and inherited retinal disorders caused by IMPDH1 mutations.
Notably, IMPDH1 is a therapeutic target for immunosuppressive and antiviral drugs (e.g., mycophenolic acid), making its antibodies valuable in drug development studies. Cross-reactivity with IMPDH2 and species-specific variations (human, mouse, rat) require careful experimental design. Post-translational modifications, such as phosphorylation, may also affect antibody binding, necessitating validation under specific conditions. Overall, IMPDH1 antibodies serve as key reagents for exploring nucleotide metabolism, disease mechanisms, and targeted therapies.
×
